Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies

Trial Profile

A Phase I, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Epinephrine (Primary) ; Epinephrine
  • Indications Anaphylaxis
  • Focus Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 14 Jun 2018 Results presented in an INSYS Therapeutics media release.
    • 12 Dec 2017 New trial record
    • 07 Dec 2017 According to a company media release, the first patient has been enrolled in this trial. INSYS expects enrollment in the study to be complete in the first quarter of 2018, with initial results for all enrolled patients available by February.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top